A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with "triple-negative" (HR and Her2 negative) operable breast cancer. TENEO Study

Trial Profile

A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with "triple-negative" (HR and Her2 negative) operable breast cancer. TENEO Study

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2016

At a glance

  • Drugs Cetuximab (Primary) ; Docetaxel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TENEO
  • Most Recent Events

    • 19 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Aug 2012 Additional lead trial investigators added as reported by ClinicalTrials.gov record.
    • 03 Jul 2012 Official title amended as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top